Atossa Therapeutics (NASDAQ:ATOS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday. Atossa Therapeutics Stock Performance Shares of NASDAQ ATOS opened at $1.24 on Friday. Atossa Therapeutics has a 1 year low of $0.50 and a […]
Related Keywords
, Jpmorgan Chase Co , Atossa Therapeutics Inc , First Republic Investment Management Inc , Renaissance Technologies , Atossa Therapeutics Company Profile , Charles Schwab Investment Management Inc , Atossa Therapeutics , Get Free Report , Schwab Investment Management , Street Corp , First Republic Investment Management , Republic Investment Management , Atossa Therapeutics Daily , Nasdaq Atos , Datos , Medical , Downgrade , Stocknews Com ,
comparemela.com © 2020. All Rights Reserved.